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The beneficial effects of inhaled corticosteroids in the treatment of asthma are well established. A potent topical 
anti-inflammatory action is assumed to underlie the therapeutic effect, given that these agents alter the number and 
function of a range of inflammatory cells and markers in airway biopsies. This activity profile is shown by all 
inhaled corticosteroids, in a variety of patient types and study designs. Thus, treatment with inhaled corticosteroids 
leads to consistent reductions in the number and activation of mast cells and eosinophils in biopsy specimens. Other 
relevant findings include reductions in T-lymphocytes, which contribute to chronic inflammation via the secretion 
of pro-inflammatory cytokines (some of which are responsible for eosinophil accumulation and activation). Inhaled 
corticosteroids may therefore act by down-regulating immunoreactivity, so reducing activation of T lymphocytes 
and (consequently) eosinophils. There is considerable interest in whether corticosteroids can inhibit or reverse some 
structural changes in the airways, including basement membrane thickening, collagen deposition and increased 
airway vascularity; it has been suggested that these changes may contribute towards airway hyperresponsiveness 
and irreversible airway obstruction. In summary, inhaled corticosteroids have a broad spectrum of anti- 
inflammatory activity in asthma patients, but the relationship between changes in clinical and immunopathological 
parameters, particularly in the long-term, requires further study. 
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vascularity. 
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Introduction 
Asthma is characterized pathologically by inflammation of 
the airways, associated with epithelial fragility and thicken- 
ing of the reticular basement membrane, which in turn are 
thought to give rise to the clinical features of the disease 
(variable airway obstruction and hyperresponsiveness to 
various stimuli). The pivotal role of inflammation in the 
pathogenesis of asthma provides theoretical justification for 
the use of inhaled corticosteriods, which are known to exert 
a potent anti-inflammatory effect. These agents are there- 
fore considered first-line therapy for the most patients with 
asthma (1,2), in the belief that if chronic inflammation can 
be suppressed then the associated short- and long-term 
consequences could be prevented. However, the mechan- 
isms by which inhaled corticosteroids exert their anti- 
inflammatory activity are not fully understood. For 
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example, it remains unclear which components of the 
inflammatory process are first affected by these agents, and 
which are most sensitive in terms of response to treatment. 
This review discusses the anti-inflammatory profile of 
inhaled corticosteroids, with a view to further under- 
standing their mechanism of action, based on the findings 
of endobronchial biopsy studies in patients with asthma. 
Review of biopsy studies 
EFFECT ON MAST CELLS AND 
EOSINOPHILS 
It is well established that bronchial inflammation in asthma 
is characterized by increased numbers of mast cells, 
eosinophils and T-lymphocytes. Mast cells play an im- 
portant role in the immediate asthmatic reaction to 
allergens (3), which is mediated by the release of powerful 
smooth muscle and vasoactive mediators such as histamine, 
prostaglandins and cysteinyl leukotrienes (4). Mast cell 
activation also leads to the release of chemoattractants for 
eosinophils; these cells release granular proteins (e.g. major 
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basic protein and eosinophil cationic protein) that are toxic 
to the airway epithelium. The number of mast cells, 
eosinophils and T lymphocytes (along with the extent of 
their activation) has therefore been a major focus of 
endobronchial biopsy assessment in studies of inhaled 
corticosteroids, as discussed below. 
Several inhaled corticosteroids are presently available, 
each of which has undergone evaluation in terms of 
endobronchial biopsy findings during treatment. For 
example, treatment with inhaled budesonide 800,~g twice 
daily was associated with a significant decrease in 
eosinophils in biopsy specimens from patients with mild 
asthma (5). A small placebo-controlled study of mildly 
asthmatic patients reported that 4 months of treatment with 
inhaled beclomethasone dipropionate (BDP) 500 pg twice 
daily led to significant reductions in the number of both 
mast cells and eosinophils, including the activated fraction 
(6). Hoshino et al. (7) also reported significant decreases in 
the number of activated eosinophils and mast cells in 
biopsy samples from patients treated with BDP for atopic 
asthma. These findings confirm the results of earlier studies, 
in which BDP significantly reduced the number of 
eosinophils in the epithelium and lamina propria of biopsy 
samples from asthmatic patients (8). 
Fluticasone propionate (FP) is an inhaled corticosteroid 
that is highly effective in the treatment of asthma (9). 
Numerous studies have reported biopsy findings following 
treatment with this agent. In a placebo-controlled study of 
patients with mild asthma, for example, Li et al. reported 
that treatment for 6 weeks with inhaled FP 25Opg twice 
daily reduced the number of total eosinophils (EGl +) and 
mast cells by 53% and 29%, respectively (10). Similar 
findings were observed by Gizycki et al. (11) who examined 
the effect of FP 250~18 twice daily for 6 weeks on the late 
phase response to inhaled allergen; FP reduced numbers of 
eosinophils and mast cells in bronchial biopsies but an 
increased influx of neutrophils was also apparent, the 
clinical relevance of which is unclear. Olivieri et al. (12) also 
reported that treatment with inhaled FP was associated 
with a significant reduction in the number of eosinophils 
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and mast cells (including the proportion of degranulated 
mast cells) in biopsy specimens, whereas placebo had no 
effect (Fig. 1). Evidence for an anti-inflammatory effect of 
FP was strengthened by the reductions in levels of 
mediators and numbers of activated cells in bronchoalveo- 
lar lavage (12). 
Although inhaled corticosteroids are effective in the 
treatment of asthma, there is some evidence of ongoing 
airway inflammation despite maintenance therapy (13) 
which suggests that some components of airway inflamma- 
tion are less sensitive to inhaled corticosteroids. 
The effect of inhaled FP on airway inflammation at the 
maximum recommended dosage of 1000 pg twice daily was 
recently investigated in two studies (14,15). In the study by 
Booth et al. (14), in which patients with mild-to-moderate 
asthma received inhaled FP for 3 months, significant 
improvements in lung function were paralleled by a 
reduction of activated eosinophils (EG2+) in the lamina 
propria of bronchial biopsies. Differences in inflammatory 
indices from bronchoalveolar lavage were less conclusive, 
although a trend towards a reduction in eosinophils and 
mast cells was apparent (14). Lim et al. (5) reported similar 
findings in a study with budesonide: whilst eosinophil 
numbers in biopsy sections from patients with mild asthma 
were decreased, eosinophil counts in bronchoalveolar 
lavage were essentially unchanged. Faul et al. (15) were 
the first to test functional and immunological effects of an 
inhaled corticosteroid at successive timepoints within the 
same population of asthmatic patients. The numbers of 
EGl + and EG2+ eosinophils in the bronchial wall were 
reduced from baseline within 2 weeks of commencing 
treatment with FP, accompanied by improvements in lung 
function. Thereafter, no further improvements in lung 
function were recorded. Immunohistologically, however, 
the improvement offered by FP was progressive; thus, the 
reduction in activated eosinophils (EG2+) was only 
significant after 8 weeks of treatment. The reasons for this 
complex relationship between improvement in lung func- 
tion and immunological abnormalities during inhaled 
corticosteroid therapy are not fully understood; however, 
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FIG. 1. Effect of inhaled fluticasone propionate (250 pg twice daily for 6 weeks) on mean ( f SEM) (a) eosinophil and (b) mast 
cell counts in bronchial biopsies from patients with mild asthma. **P<O.Ol vs. baseline (12). Baseline (n), after treatment 
(1). 
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the reduction in airway inflammation after 2 weeks may 
correlate with other outcome measures such as bronchial 
hyperresponsiveness or asthma exacerbations. 
Although not a biopsy study, the findings of Meijer et al. 
(16) add to our understanding of the effect of inhaled 
corticosteroids on airways inflammation. These authors 
used the technique of induced sputum, in which patients 
inhale nebulized hypertonic saline and are then encouraged 
to cough and expectorate sputum, to compare the effects of 
inhaled FP (at dosages of 500 and 200 pg day-‘) versus oral 
prednisolone (30mgday-‘) on airways inflammation. 
Overall, there was a dose-dependent reduction in eosinophil 
numbers and eosinophil cationic protein levels in sputum 
after 2 weeks of treatment with inhaled FP. At the higher 
FP dosage, these changes were similar to those observed for 
oral prednisolone (Fig. 2), and were accompanied by 
improvements in lung function and hyperresponsiveness 
that were significantly greater than those in the predniso- 
lone group (16). 
EFFECT ON T LYMPHOCYTES 
The chronic airway inflammation in patients with asthma is 
also associated with prolonged residence in the bronchial 
wall of activated T-lymphocytes (17). These cells therefore 
represent further targets for therapeutic intervention, and 
the effect of inhaled corticosteroids on T-lymphocytes has 
been evaluated in several biopsy studies in asthmatic 
patients (10,14,15). For example, Faul et al. (15) reported 
that 8 weeks of treatment with inhaled FP (1000,ug twice 
daily) produced reductions in the number of T-lymphocytes 
and CD45RO+ T-lymphocytes in the bronchial wall 
within 2 weeks of commencing therapy. Given the 
concomitant profile of reductions in eosinophils over the 
&week treatment period (as described above), the authors 
speculated that the reduction in eosinophils occurred as a 
consequence of the initial decrease in the number of 
CD45RO+ T-lymphocytes in the mucosa. This is in 
accordance with the knowledge that T-cell-derived cyto- 
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kines, such as interleukin-5 and granulocyte macrophage- 
colony-stimulating factor (GM-CSF), are responsible for 
accumulation and prolonged survival of eosinophils in the 
airways (1819). 
The primary mechanism of action of inhaled corticoster- 
oids may therefore be to down-regulate immunoreactivity, 
thereby reducing T-lymphocyte function and, consequently, 
eosinophil activation. This effect may be dose-dependent, 
given that studies with lower doses of inhaled corticoster- 
oids (even allowing for differences in potency) failed to 
demonstrate an effect on helper or activated helper T-cells 
despite reductions in total and activated eosinophils (6). 
Indeed, Bamford et al. (20) recently reported that although 
inhaled corticosteroid therapy, in this case BDP (200- 
1500 pg day-‘), can effectively normalize elevated numbers 
of mast cells and eosinophils in airway biopsies, patients 
may remain symptomatic. Other studies with BDP, 
however, reported significant decreases in CD3 + and 
CD4+ T-cells during 12 weeks of treatment, which were 
associated with significant improvement in airway respon- 
siveness in patients with atopic asthma (7). It is interesting 
to speculate whether the absence of an effect on T- 
lymphocytes may explain continuing symptoms in some 
asthmatic patients despite inhaled corticosteroid therapy, 
since recent studies show that persistent T-cell activation is 
a prominent feature of severe asthma (21). Interestingly, 
Vrugt et al. (21) also showed the absence of prominent 
mucosal eosinophilia in patients with severe asthma, 
indicating the likely contribution of other inflammatory 
cells or mechanisms to the continuing disease in these 
patients. Possible mechanisms are discussed in the follow- 
ing sections. 
EPITHELIUM 
Bronchial epithelium plays an important role in the 
regulation of airway function (22). For example, epithelial 
cells are damaged and shed during asthmatic exacerbations, 
leading to increased permeability of airways to inhaled 
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FIG. 2. Changes from baseline in (a) sputum eosinophil numbers and (b) sputum concentrations of eosinophil cationic 
protein (ECP) after 2 weeks’ treatment with either oral prednisolone (30 pg day- ‘) or inhaled fluticasone propionate (500 or 
2000 pg day-‘) in patients with asthma. Values are medians with interquartile ranges. *P < 0.05 vs. fluticasone propionate 
500 ,ug. [Adapted from (16), with permission]. 
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allergens and exposure of afferent nerve endings. The 
release of sensory neuropeptides by such airway neurones is 
thought to contribute to ongoing inflammation, broncho- 
constriction, microvascular leakage and secretion of mucus. 
Epithelial damage is probably mediated via the release of 
basic proteins from activated eosinophils and proteolytic 
enzymes from mast cells, leading to the release of a range of 
mediators, cytokines, chemokines and growth factors that 
act as chemoattractants, inhibit apoptosis of eosinophils 
and stimulate expression of cellular adhesion molecules. 
Maintenance of epithelial integrity and function therefore 
represents a target for anti-asthma therapy. There is 
evidence to suggest that inhaled corticosteroids reduce 
epithelial damage and shedding, as shown by a reduction in 
epithelial cell counts in bronchoalveolar lavage following 
treatment with inhaled corticosteroids (14,23). This has also 
been demonstrated in biopsy studies, in which 10 years of 
treatment with inhaled corticosteroids was associated with 
improvements in epithelial abnormalities (24). 
AIRWAY REMODELLING 
A large body of evidence supports the fact that asthma is a 
chronic inflammatory disorder of the airways involving 
release of mediators from both mast cells and eosinophils, 
and orchestrated by T-lymphocytes. A feature of the 
chronic inflammatory process in asthma is airway remodel- 
ling (25) which is characterized by extensive deposition of 
collagen beneath the sub-epithelial layer. Fibroblasts 
appear to play an important role in this thickening of the 
basement membrane (26) which, in conjunction with 
smooth muscle hypertrophy/hyperplasia, has been sug- 
gested to contribute towards persistent hyperresponsiveness 
and irreversible obstruction of the airways (27). Indeed, 
increased basement membrane thickness has been shown to 
be positively correlated with airway reactivity to methacho- 
line and negatively correlated with forced expiratory 
volume in 1 set (FEVi) (26,28); however, Chu et al. showed 
no correlation between basement membrane thickness and 
asthma severity (29). 
A number of studies have investigated whether inhaled 
corticosteroids can alter the thickness of the basement 
membrane. In a small group of patients with mild asthma, 
no alteration in thickness was seen after treatment with 
budesonide 200 ,ug for 4 weeks (13). Although the study by 
Trigg et al. suggested that treatment with BDP for 4 
months reduced basement membrane thickness, this was 
measured using an antibody to a collagen component 
rather than by the conventional method of light or electron 
microscopy (6). Olivieri et al. have also suggested that 
fluticasone propionate may reduce basement membrane 
thickness, but differences in the baseline measurements of 
thickness between the treated and placebo groups confound 
interpretation of this study (12). Beneficial effects of an 
inhaled corticosteroid were reported by Laitinen et al. who 
showed that the thickness of the tenascin layer in the 
basement membrane of patients with seasonal asthma fell 
by 39% after treatment with budesonide for 4-6 weeks 
during the pollen season (30). More studies are needed 
before a definite effect of inhaled corticosteroids on 
basement membrane thickening can be proven. 
Increased vascularity is another aspect of the structural 
remodelling that occurs during chronic inflammation of the 
airways (31) and may have several consequences for 
patients with asthma. The most notable is a possible effect 
on airway responsiveness, since a small increase in thickness 
of the airway wall (e.g. because of oedema and/or 
microvascular engorgement) may lead to pronounced 
narrowing of the airway lumen during smooth muscle 
contraction (32). As described above, inhaled corticoster- 
oids potentially reduce airway remodelling although data 
pertaining to their effect on increased airway vascularity are 
limited. In one recent study, Orsida et al. (33) reported a 
significant increase in the density of vessels in the lamina 
propria of mildly asthmatic patients who were not receiving 
inhaled corticosteroids compared with non-asthmatic con- 
trols, and vessel density was strongly correlated with both 
lung function and hyperresponsiveness. Interestingly, those 
patients being treated with an inhaled corticosteroid 
showed a decreased level of vascularity (versus those not 
on such treatment), and this effect showed a trend towards 
dose-dependency. Reduction of airway wall vascularity 
may therefore contribute to the therapeutic efficacy of 
inhaled corticosteroids, particularly at high dosages. 
Further studies are clearly warranted to delineate the 
mechanism of this anti-angiogenic effect. 
Conclusions 
The range of anti-inflammatory properties demonstrated 
for inhaled corticosteroids in biopsy studies on asthmatic 
patients can be summarized as follows: reduction in 
numbers of mast cells (most pronounced in atopic patients); 
reduction in numbers and activation of eosinophils; 
reduction in numbers and function of T-lymphocytes 
(particulary CD4 + cells); improved epithelial morphology 
and reduction in epithelial cell activation, and some degree 
of reversal of airway remodelling. The combination of 
activities has been shown consistently among different 
patient types and in a variety of study designs. 
Overall, these findings indicate that inhaled corticoster- 
oids have a broad spectrum of anti-inflammatory effects, 
which supports their use as first-line therapy for asthma. 
Further studies are required to investigate the mechanism 
of continued inflammation in severe asthma, and the 
effect of inhaled corticosteroids on structural changes in 
the airways and how these changes relate to chronic 
inflammation. 
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